A user named Medical_Opinion8120, a 23-year-old female, is experiencing hair loss potentially due to a past accutane course. She has tried minoxidil without success and is currently taking iron and zinc supplements.
The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.
A 19-year-old diagnosed with AGA was refused finasteride by a dermatologist who cited fertility concerns and prescribed minoxidil, vitamins, and shampoos instead. The user is unsure about using minoxidil and considers finding another dermatologist.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
The conversation discusses hair loss treatments for a woman experiencing androgenetic alopecia and seborrheic dermatitis, with suggestions including low-dose oral minoxidil, dutasteride, and hormone replacement therapy. The user is seeking advice due to intolerance to spironolactone and topical minoxidil, and concerns about low testosterone and DHT levels.
The user experienced microinflammation on the crown after using mometasone furoate (Nasonex) nasal spray. They are seeking information on the relationship between this corticosteroid and hair loss.
A user shared their positive experience using a cheap dermastamp from Aliexpress for microneedling, finding it effective and mostly painless. Other users discussed their experiences with similar products, cleaning methods, and needle lengths, with some noting differences in product quality between sellers.
The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.
DHT Itch and its link to balding, with various treatments such as finasteride being discussed. Members shared their experiences of scalp itch before and after taking 5AR inhibitors, and potential underlying causes such as seborrheic dermatitis were discussed.
The user is experiencing scalp itching from a PG ethanol base in their hair loss treatment, which includes 0.025% finasteride and 2.5% minoxidil, and is seeking alternatives without PG or ethanol. Suggestions include Zeuss non-PG foam and Ulo, which do not use PG or hydrocortisone.
The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.
Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.
Hair oils can cause severe allergic reactions, as seen in Jermel Brown's case, leading to significant health issues and legal action for damages. Users discussed concerns about various hair oils, including Mielle and Kiehl's, with some experiencing hair loss and others using treatments like Minoxidil and Finasteride to address damage.
Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.
The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.
Using hair fibers daily is generally fine, but it's important to choose a quality keratin-based product to avoid scalp irritation. The user combines hair fibers with a regimen of finasteride, minoxidil, microneedling, and ketoconazole.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.
The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.
The conversation discusses hair loss concerns, specifically traction alopecia and hair loss from acne. It mentions that sleeping on one side is unlikely to cause traction alopecia.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
The user is anxious about potential side effects of finasteride, particularly PFS, and is considering reinstating it for hair loss treatment. They experienced anxiety-induced side effects previously and are seeking advice on overcoming their fear of restarting finasteride.
The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.